NEUROCRINE BIOSCIENCES INC 4

Chief Regulatory Officer Ingrid Delaet exercised 4,367 options at $106.02 and sold 4,367 Neurocrine Biosciences (NBIX) shares at $181.02 on July 10, 2026 under a Rule 10b5-1 plan.

On July 10, 2026, Neurocrine Biosciences Inc. Chief Regulatory Officer Ingrid Delaet exercised 4,367 non-qualified stock options at $106.02 per share, acquiring an equal number of common shares, and on the same day sold 4,367 common shares at $181.02 per share under a pre-established Rule 10b5-1 trading plan, resulting in a net unchanged share count but a realization of approximately $328,000 in gross sale proceeds and about $328,000 in intrinsic value from the option exercise. Following these transactions, she reported direct ownership of 16,225 common shares, valued at roughly $2.94 million based on the reported sale price, and the options exercised originated from a 2021 grant that vested over time according to the company’s equity compensation schedule.

Filing Facts

CIK

914475

Ticker

NBIX

Form

4

Source Type

fda

Accession

0001965808-26-000013

Alert Tier

6